DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK, B. POST and at. ALL. Trial of Deferiprone in Parkinson’s Disease. The New England Journal of medicine. USA: Massachusetts Medical Society, 2022, vol. 387, NA, p. 2045-2055. ISSN 1533-4406. Available from: https://dx.doi.org/10.1056/NEJMoa2209254.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Trial of Deferiprone in Parkinson’s Disease
Authors DEVOS, D., J. LABREUCHE, O. RASCOL, J.-C. CORVOL, A. DUHAMEL, P. Guyon DELANNOY, W. POEWE, Y. COMPTA, N. PAVESE, E. RŮŽIČKA, P. DUŠEK, B. POST and at. ALL.
Edition The New England Journal of medicine, USA, Massachusetts Medical Society, 2022, 1533-4406.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30230 Other clinical medicine subjects
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW FAIRPARK II
Impact factor Impact factor: 158.500
RIV identification code RIV/00216224:14110/22:00127673
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1056/NEJMoa2209254
Keywords (in Czech) Parkinsonova choroba; neurodegenerativní porucha; FAIRPAK II; klinické hodnocení;
Keywords in English Parkinson’s Disease; neurodegenerative disorder; FAIRPAK II; clinical trial;
Tags MU, RIV, UK LF PRAHA, UK PRAHA, user
Tags International impact, Reviewed
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 4/1/2023 11:47.
Abstract
BACKGROUND Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
Links
90128, large research infrastructuresName: CZECRIN III
PrintDisplayed: 27/4/2024 01:17